Tyra biosciences reports third quarter 2023 financial results and highlights

- enrollment and dose escalation ongoing in surf301 phase 1/2 oncology - - presented additional preclinical data on tyra-300 in achondroplasia at asbmr and ashg - - first patient to be dosed in tyra-200 phase 1 by ye 2023 - - strong cash position of $215.7 million as of q3 2023 - carlsbad, calif. , nov. 7, 2023 /prnewswire/ -- tyra biosciences, inc. (nasdaq: tyra), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in fibroblast growth factor receptor (fgfr) biology, today reported financial results for the quarter ended september 30, 2023 and highlighted recent corporate progress.
TYRA Ratings Summary
TYRA Quant Ranking